Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder

Michael Camilleri, Rita K. Balm, Alan R. Zinsmeister

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background/Aims: Reasons for the variable efficacy of prokinetic agents in the treatment of chronic intestinal motility disorders are unclear. The aim of this study was to assess the influence of extrinsic autonomic neuropathy and motility patterns on the symptom response to cisapride in 42 such patients. Methods: A randomized, double-blind, placebo-controlled, two-dose (10 and 20 mg, three times daily), 12-week study included (1) measurement of autonomic (including abdominal vagal) function; (2) standardized 5-hour upper gastrointestinal manometry; and (3) assessment of symptoms based on visual analog scale at baseline and 6 and 12 weeks. Statistical analysis compared symptom response among treatment and autonomic dysfunction groups and assessed the influence of absence of migrating motor complexes and presence of postprandial antral hypomotility on symptomatic responses to cisapride. Results: There was no significant overall effect of cisapride in the entire group of 42 patients. Generalized sympathetic and vagal dysfunctions influence the response of patients with neuropathic chronic intestinal motility disorder to two doses of cisapride. Conclusions: Idiopathic intestinal motility disorder, unassociated with abdominal vagal dysfunction, is more likely to respond to cisapride. Detailed characterization of patient subgroups is crucial to designing treatment trials in patients with small bowel motility disorders.

Original languageEnglish (US)
Pages (from-to)916-923
Number of pages8
JournalGastroenterology
Volume106
Issue number4
StatePublished - 1994

Fingerprint

Cisapride
Gastrointestinal Motility
Migrating Myoelectric Complexes
Symptom Assessment
Manometry
Visual Analog Scale
Therapeutics
Placebos

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder. / Camilleri, Michael; Balm, Rita K.; Zinsmeister, Alan R.

In: Gastroenterology, Vol. 106, No. 4, 1994, p. 916-923.

Research output: Contribution to journalArticle

@article{7e6463e0b63543c485e1f0f5bb2f2d21,
title = "Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder",
abstract = "Background/Aims: Reasons for the variable efficacy of prokinetic agents in the treatment of chronic intestinal motility disorders are unclear. The aim of this study was to assess the influence of extrinsic autonomic neuropathy and motility patterns on the symptom response to cisapride in 42 such patients. Methods: A randomized, double-blind, placebo-controlled, two-dose (10 and 20 mg, three times daily), 12-week study included (1) measurement of autonomic (including abdominal vagal) function; (2) standardized 5-hour upper gastrointestinal manometry; and (3) assessment of symptoms based on visual analog scale at baseline and 6 and 12 weeks. Statistical analysis compared symptom response among treatment and autonomic dysfunction groups and assessed the influence of absence of migrating motor complexes and presence of postprandial antral hypomotility on symptomatic responses to cisapride. Results: There was no significant overall effect of cisapride in the entire group of 42 patients. Generalized sympathetic and vagal dysfunctions influence the response of patients with neuropathic chronic intestinal motility disorder to two doses of cisapride. Conclusions: Idiopathic intestinal motility disorder, unassociated with abdominal vagal dysfunction, is more likely to respond to cisapride. Detailed characterization of patient subgroups is crucial to designing treatment trials in patients with small bowel motility disorders.",
author = "Michael Camilleri and Balm, {Rita K.} and Zinsmeister, {Alan R.}",
year = "1994",
language = "English (US)",
volume = "106",
pages = "916--923",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder

AU - Camilleri, Michael

AU - Balm, Rita K.

AU - Zinsmeister, Alan R.

PY - 1994

Y1 - 1994

N2 - Background/Aims: Reasons for the variable efficacy of prokinetic agents in the treatment of chronic intestinal motility disorders are unclear. The aim of this study was to assess the influence of extrinsic autonomic neuropathy and motility patterns on the symptom response to cisapride in 42 such patients. Methods: A randomized, double-blind, placebo-controlled, two-dose (10 and 20 mg, three times daily), 12-week study included (1) measurement of autonomic (including abdominal vagal) function; (2) standardized 5-hour upper gastrointestinal manometry; and (3) assessment of symptoms based on visual analog scale at baseline and 6 and 12 weeks. Statistical analysis compared symptom response among treatment and autonomic dysfunction groups and assessed the influence of absence of migrating motor complexes and presence of postprandial antral hypomotility on symptomatic responses to cisapride. Results: There was no significant overall effect of cisapride in the entire group of 42 patients. Generalized sympathetic and vagal dysfunctions influence the response of patients with neuropathic chronic intestinal motility disorder to two doses of cisapride. Conclusions: Idiopathic intestinal motility disorder, unassociated with abdominal vagal dysfunction, is more likely to respond to cisapride. Detailed characterization of patient subgroups is crucial to designing treatment trials in patients with small bowel motility disorders.

AB - Background/Aims: Reasons for the variable efficacy of prokinetic agents in the treatment of chronic intestinal motility disorders are unclear. The aim of this study was to assess the influence of extrinsic autonomic neuropathy and motility patterns on the symptom response to cisapride in 42 such patients. Methods: A randomized, double-blind, placebo-controlled, two-dose (10 and 20 mg, three times daily), 12-week study included (1) measurement of autonomic (including abdominal vagal) function; (2) standardized 5-hour upper gastrointestinal manometry; and (3) assessment of symptoms based on visual analog scale at baseline and 6 and 12 weeks. Statistical analysis compared symptom response among treatment and autonomic dysfunction groups and assessed the influence of absence of migrating motor complexes and presence of postprandial antral hypomotility on symptomatic responses to cisapride. Results: There was no significant overall effect of cisapride in the entire group of 42 patients. Generalized sympathetic and vagal dysfunctions influence the response of patients with neuropathic chronic intestinal motility disorder to two doses of cisapride. Conclusions: Idiopathic intestinal motility disorder, unassociated with abdominal vagal dysfunction, is more likely to respond to cisapride. Detailed characterization of patient subgroups is crucial to designing treatment trials in patients with small bowel motility disorders.

UR - http://www.scopus.com/inward/record.url?scp=0028216244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028216244&partnerID=8YFLogxK

M3 - Article

C2 - 8143996

AN - SCOPUS:0028216244

VL - 106

SP - 916

EP - 923

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -